Investigating heart and lung effects of radiotherapy in cancer patients

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to assess the incidence and progression of pulmonary hypertension (PH) as a potential side effect of thoracic radiotherapy in patients with oesophageal cancer and non-small cell lung cancer (NSCLC). Using diagnostic tools such as echocardiography, cardiac MRI, and serum biomarkers, the study will relate these physiological changes to the radiation dose received by the heart and lungs. The goal is to understand the characteristics of radiation-induced PH and identify risk factors to optimize treatment and improve patient outcomes.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Patients with oesophageal cancer in the mid or distal oesophagus and patients with NSCLC stage IIA-III or NSCLC stage IV with limited brain metastases (treatable with surgery or stereotactic radiosurgery) or SCLC limited disease (stage I-IIIB)
* Scheduled for external-beam radiotherapy with curative intention.
* WHO 0-2.
* Age \>= 18 years
* Written informed consent.

Exclusion Criteria:

* No heart failure in the last 2 months
* No pulmonary embolism in the last 2 months
* COPD gold IV
* BMI \>35
* History of thoracic radiotherapy
* Noncompliance with any of the inclusion criteria - For MRI part: Contra indications for MRI

For MRI part:

• contra-indications for MRI

Where it's running

• Radboud UMC
  Nijmegen, Gelderland, Netherlands Recruiting
• Universitaire Ziekenhuizen Leuven
  Leuven, Belgium Terminated
• NHS Greater Glasgow and Clyde
  Glasgow, United Kingdom Terminated

Study contacts

• Study coordinator: CT Muijs, MD PhD
• Email: c.t.muijs@umcg.nl
• Phone: 00315036115179

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Reducing dosing frequency of immune checkpoint inhibitors in advanced cancers

  This study is testing if giving immune checkpoint inhibitors less often can still help people with advanced cancers feel better while making treatment easier and cheaper.

  Recruiting Phase 2 National University Hospital, Singapore · Singapore · NCT06422403

• Patient-specific MRD liquid biopsy for resected NSCLC

  This study tests a personalized MRD blood and bronchial washing test after surgery to see if it can signal recurrence earlier in people with resected NSCLC.

  Recruiting Yonsei University · Yongin-si, Gyeonggi-do and 2 other locations · NCT07921888

• Osimertinib Plus SRS/SRT for EGFR-Mutant NSCLC with Symptomatic Brain Metastases

  This study tests whether adding targeted brain radiotherapy to osimertinib helps control brain metastases in adults with EGFR-mutant NSCLC and neurological symptoms.

  Recruiting Phase 2 Cho Ray Hospital · Ho Chi Minh City · NCT07911449

• Dato-DXd in solid tumors (Urothelial Cancer and KRAS-mutant NSCLC) in two sub-studies

  This study tests Datopotamab Deruxtecan (Dato-DXd) alone or with other cancer drugs in people with urothelial cancer or KRAS-mutant non-small cell lung cancer.

  Recruiting Phase 1/2 Daiichi Sankyo · Taichung · NCT07890714

• SI-B036 safety test in advanced and metastatic solid tumors

  This early-phase study checks whether SI-B036 is safe and tolerable in adults with advanced or metastatic solid cancers who have had prior therapy.

  Recruiting at 4 sites Phase 1 SystImmune Inc. · New Haven, Connecticut and 6 other locations · NCT07857616

• Postoperative EGFR-TKI Therapy for EGFR-mutant NSCLC Following Surgery

  This registry tests whether giving an EGFR-TKI after surgery helps adults with EGFR-mutant, high-risk early-stage NSCLC.

  Recruiting Tongji Hospital · Wuhan, Hubei · NCT07837739

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.